{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"108-252-998-779-369","frontPageModel":{"patentViewModel":{"ref":{"entityRefId":"108-252-998-779-369","entityRefType":"PATENT"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":11844,"type":"PATENT","title":"University of Kansas Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":8584,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8456,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately: univ* AND Kansas. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 1781
Search Applicants and Owners separately: univ* AND Kansas. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 1781
identifying an individual with a disorder associated with GPRC6A; and\n
administering to the individual an agent capable of regulating an expression level and/or activity of GPRC6A."],"number":1,"annotation":false,"claim":true,"title":false},{"lines":["The method of treating of claim 1, wherein said regulating increases or decreases the concentration of a sex hormone within said individual."],"number":2,"annotation":false,"claim":true,"title":false},{"lines":["The method of treating of claim 1, wherein said regulating is upregulating said expression level and/or activity of said GPRC6A."],"number":3,"annotation":false,"claim":true,"title":false},{"lines":["The method of treating of claim 3, wherein said upregulating is effected by administering to the individual an androgenergic agonist of said GPRC6A."],"number":4,"annotation":false,"claim":true,"title":false},{"lines":["The method of treating of claim 3, wherein said disorder is an estrogen responsive breast cancer or ovarian cancer and said upregulating reduces the concentration of estradiol in the individual."],"number":5,"annotation":false,"claim":true,"title":false},{"lines":["The method of treating of claim 3, wherein said disorder is osteoporosis or osteopenia and said upregulating increases bone density in said individual."],"number":6,"annotation":false,"claim":true,"title":false},{"lines":["The method of treating of claim 3, wherein said disorder is an metabolic syndrome and said upregulating increases lean body mass and/or decreases body fat mass in the individual."],"number":7,"annotation":false,"claim":true,"title":false},{"lines":["The method of treating of claim 3, wherein said disorder is diabetes."],"number":8,"annotation":false,"claim":true,"title":false},{"lines":["The method of treating of claim 3, wherein said upregulating is effected by at least one approach selected from the group consisting of: (a) expressing in cells of said individual an exogenous polynucleotide encoding at least a functional portion of GPRC6A; (b) increasing expression of endogenous GPRC6A in said individual; (c) increasing endogenous GPRC6A activity in said individual; (d) introducing an exogenous polypeptide including at least a functional portion of GPRC6A to said individual; and (e) administering GPRC6A-expressing cells into said individual."],"number":9,"annotation":false,"claim":true,"title":false},{"lines":["The method of treating of claim 1, wherein said regulating is down-regulating said expression level and/or activity of said GPRC6A."],"number":10,"annotation":false,"claim":true,"title":false},{"lines":["The method of treating of claim 10, wherein said downregulating is effected by administering to said individual an androgenergic antagonist of said GPRC6A."],"number":11,"annotation":false,"claim":true,"title":false},{"lines":["The method of treating of claim 10, wherein said disorder is prostate cancer."],"number":12,"annotation":false,"claim":true,"title":false},{"lines":["The method of treating of claim 10, wherein said disorder is benign prostatic hypertrophy."],"number":13,"annotation":false,"claim":true,"title":false},{"lines":["The method of treating of claim 10, wherein said downregulating is effected by introducing into said individual an agent selected from the group consisting of: (a) a molecule that binds said GPRC6A; (b) an enzyme which cleaves said GPRC6A; (c) an antisense polynucleotide capable of specifically hybridizing with at least part of an mRNA transcript encoding GPRC6A; (d) a ribozyme which specifically cleaves at least part of an mRNA transcript encoding GPRC6A; (e) a small interfering RNA (siRNA) molecule which specifically cleaves at least part of a transcript encoding GPRC6A; (f) a non-functional analogue of at least a catalytic or binding portion of said GPRC6A; and (g) a molecule which prevent GPRC6A activation or substrate binding."],"number":14,"annotation":false,"claim":true,"title":false},{"lines":["A method for upregulating GPRC6A in a subject, comprising:\n
administering to the subject an androgenergic agonist of said GPRC6A in a therapeutically effective amount to upregulate GPRC6A."],"number":15,"annotation":false,"claim":true,"title":false},{"lines":["A method as in claim 15, wherein the androgenergic agonist is selected from the group consisting of androgens, steroid hormones, androgenic hormones, anabolic steroids, testoids, testosterones, 19-carbon steroids, dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulfate (DHEA-S), androstenedione, androstenediones, androstenediol, androsterone, dihydrotestosterone, androstanolone, fluoxymesterone, mesterolone, methyltestosterone, selective androgen receptor modulators (SARM), andarine, BMS-564,929, LGD-226, ostarine, S-40503, brimonidine tartrate, dexamethasone, indeloxazine hydrochloride, salts thereof, combinations thereof, and the like."],"number":16,"annotation":false,"claim":true,"title":false},{"lines":["A method for downregulating GPRC6A in a subject, comprising:\n
administering to the subject an androgenergic antagonist of said GPRC6A in a therapeutically effective amount to downregulate GPRC6A."],"number":17,"annotation":false,"claim":true,"title":false},{"lines":["A method as in claim 17, wherein the androgenergic antagonist is selected from the group consisting of allylestrenol, oxendolone, osaterone acetate, bicalutamide, steroidal anti-androgergic agents, medroxyprogesterone (MPA), cyproterone, cyproterone acetate (CPA), dienogest, flutamide, nilutamide, spironolactone, 5alpha-reductase inhibitors, dutasteride, finasteride, salts thereof, combinations thereof, and the like."],"number":18,"annotation":false,"claim":true,"title":false},{"lines":["A GPRC6A knockout mouse comprising a GPRC6A gene having a deleted exon 2."],"number":19,"annotation":false,"claim":true,"title":false},{"lines":["A mouse as in claim 19, wherein the mouse is heterozygous GPRC6A±."],"number":20,"annotation":false,"claim":true,"title":false},{"lines":["A mouse as in claim 19, wherein the mouse is homozygous GPRC6A−/−."],"number":21,"annotation":false,"claim":true,"title":false},{"lines":["A method for identifying a substance that modulates GPRC6A, said method comprising:\n
providing a cell expressing GPRC6A; and\n
screening the substance against the cell so as to determine whether or not the substance modulates GPRC6A."],"number":22,"annotation":false,"claim":true,"title":false},{"lines":["A method as in claim 22, further comprising screening a library of substances."],"number":23,"annotation":false,"claim":true,"title":false},{"lines":["A method as in claim 22, wherein the substance upregulates GPRC6A."],"number":24,"annotation":false,"claim":true,"title":false},{"lines":["A method as in claim 22, wherein the substance downregulates GPRC6A."],"number":25,"annotation":false,"claim":true,"title":false},{"lines":["A method as in claim 22, wherein the cell is transformed from a non-GPRC6A cell to a cell that expresses GPRC6A."],"number":26,"annotation":false,"claim":true,"title":false}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}